Aegerion Pharmaceuticals (NASDAQ:AEGR) is receiving a lot of optimism from Needham & Company on the possible approval lomitapide for the treatment of hoFH.
Needham said, "The 2010 Season of Biotech (Sep-Dec) for Aegerion was highlighted by a successful IPO in preparation for the regulatory submission in 2H11 and potential market approval of lomitapide for the treatment of hoFH in 2H12. The top-line data demonstrated impressive efficacy of lomitapide in reducing LDL-C (45%) and triglyceride (45%) with acceptable safety in an ongoing pivotal study...We view AEGR as a stock of added interest in 2011...The Company will follow the patients for a total of 78 weeks for safety and has guided a 2H11 submission timeline. We believe lomitapide has built a compelling efficacy and safety database with > 700 patients treated to date in 7 Phase 1 and 6 Phase 2 trials."
Needham & Company reiterates a "Buy" on Aegerion Pharmaceuticals, which closed Wednesday at $14.35, up $0.15, or 1.06 percent. Needham as a price target of $16 on them.
Showing posts with label Aegerion Pharmaceuticals. Show all posts
Showing posts with label Aegerion Pharmaceuticals. Show all posts
Thursday, January 6, 2011
Friday, December 3, 2010
Aegerion Pharmaceuticals' (Nasdaq:AEGR) Lomitapide Should be Catalyst
Citing the highly probable success of lomitapide, both commercially and regulatorially, Canaccord Genuity should be a strong catalyst for Aegerion Pharmaceuticals (Nasdaq:AEGR), according to Canaccord Genuity.
"We think lomitapide has a high chance of regulatory and commercial success. We think lomitapide will successfully complete the remaining safety portion of a pivotal trial and other small PK safety studies. Given HoFH’s unmet medical need, we think lomitapide will receive expedited review and approval in 2012 with a broad label. We think the drug will be appropriate for ~4,000-6,000 patients worldwide and predict worldwide peak sales of over $400M in HoFH alone," said Canaccord.
Canaccord Genuity maintains a "Buy" rating on Aegerion, which closed Thursday at $11 even. They have a price target of $16 on them.
"We think lomitapide has a high chance of regulatory and commercial success. We think lomitapide will successfully complete the remaining safety portion of a pivotal trial and other small PK safety studies. Given HoFH’s unmet medical need, we think lomitapide will receive expedited review and approval in 2012 with a broad label. We think the drug will be appropriate for ~4,000-6,000 patients worldwide and predict worldwide peak sales of over $400M in HoFH alone," said Canaccord.
Canaccord Genuity maintains a "Buy" rating on Aegerion, which closed Thursday at $11 even. They have a price target of $16 on them.
Subscribe to:
Posts (Atom)